Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Claire Saint-Cyr is active.

Publication


Featured researches published by Claire Saint-Cyr.


Arthritis Care and Research | 2010

Prevalent Vertebral Fractures among Children Initiating Glucocorticoid Therapy for the Treatment of Rheumatic Disorders

Adam M. Huber; Isabelle Gaboury; David A. Cabral; Bianca Lang; Andy Ni; David Stephure; Shayne Taback; Peter B. Dent; Janet Ellsworth; Claire LeBlanc; Claire Saint-Cyr; Rosie Scuccimarri; John Hay; Brian Lentle; M. Matzinger; Nazih Shenouda; David Moher; Frank Rauch; Kerry Siminoski; Leanne M. Ward

Vertebral fractures are an under‐recognized problem in children with inflammatory disorders. We studied spine health among 134 children (87 girls) with rheumatic conditions (median age 10 years) within 30 days of initiating glucocorticoid therapy.


Arthritis Care and Research | 2012

Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study.

Celia Rodd; Bianca Lang; Timothy Ramsay; Nathalie Alos; Adam M. Huber; David A. Cabral; Rosie Scuccimarri; Paivi Miettunen; J. Roth; Stephanie A. Atkinson; Robert Couch; Elizabeth A. Cummings; Peter B. Dent; Janet Ellsworth; John Hay; Kristin Houghton; Roman Jurencak; Maggie Larché; Claire LeBlanc; Kiem Oen; Claire Saint-Cyr; Robert Stein; David Stephure; Shayne Taback; Brian Lentle; M. Matzinger; Nazih Shenouda; David Moher; Frank Rauch; Kerry Siminoski

To determine the frequency of incident vertebral fractures (IVF) 12 months after glucocorticoid (GC) initiation in children with rheumatic diseases and to identify children at higher risk.


Arthritis Care and Research | 2010

Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort

Kiem Oen; Ciarán M. Duffy; Shirley M. L. Tse; Suzanne Ramsey; Janet Ellsworth; Gaëlle Chédeville; Anne-Laure Chetaille; Claire Saint-Cyr; David A. Cabral; Lynn Spiegel; Rayfel Schneider; Bianca Lang; Adam M. Huber; Paul Dancey; Earl D. Silverman; Alan M. Rosenberg; Bonnie Cameron; Nicole Johnson; Jean Dorval; Rosie Scuccimarri; Sarah Campillo; Ross E. Petty; Karen Watanabe Duffy; Gilles Boire; Elie Haddad; Kristin Houghton; Ronald M. Laxer; Stuart E. Turvey; Paivi Miettunen; Katherine Gross

To determine early outcomes and early improvements in a prospective inception cohort of children with juvenile idiopathic arthritis (JIA) treated with current standard therapies.


Arthritis Care and Research | 2009

Predictors of early inactive disease in a juvenile idiopathic arthritis cohort: Results of a Canadian multicenter, prospective inception cohort study

Kiem Oen; Lori B. Tucker; Adam M. Huber; Paivi Miettunen; Rosie Scuccimarri; Sarah Campillo; David A. Cabral; Brian M. Feldman; Shirley M. L. Tse; Gaëlle Chédeville; Lynn Spiegel; Rayfel Schneider; Bianca Lang; Janet Ellsworth; Suzanne Ramsey; Paul Dancey; Earl D. Silverman; Anne-Laure Chetaille; Bonnie Cameron; Nicole Johnson; Jean Dorval; Ross E. Petty; Karen Watanabe Duffy; Gilles Boire; Elie Haddad; Kristin Houghton; Claire Saint-Cyr; Stuart E. Turvey; Susanne M. Benseler; Mary Cheang

OBJECTIVE To determine early predictors of 6-month outcomes in a prospective cohort of patients with juvenile idiopathic arthritis (JIA). METHODS Patients selected were those enrolled in an inception cohort study of JIA, the Research in Arthritis in Canadian Children Emphasizing Outcomes Study, within 6 months after diagnosis. The juvenile rheumatoid arthritis core criteria set and quality of life measures were collected at enrollment and 6 months later. Outcomes evaluated included inactive disease, Juvenile Arthritis Quality of Life Questionnaire (JAQQ) scores, and Childhood Health Assessment Questionnaire (C-HAQ) scores at 6 months. RESULTS Thirty-three percent of patients had inactive disease at 6 months. Onset subtype and most baseline core criteria set measures correlated with all 3 outcomes. Relative to oligoarticular JIA, the risks of inactive disease were lower for enthesitis-related arthritis, polyarthritis rheumatoid factor (RF)-negative JIA, and polyarthritis RF-positive JIA, and were similar for psoriatic arthritis. In multiple regression analyses, the baseline JAQQ score was an independent predictor of all 3 outcomes. Other independent baseline predictors included polyarthritis RF-negative and systemic JIA for inactive disease; C-HAQ score and polyarthritis RF-positive JIA for the 6-month C-HAQ score; and active joint count, pain, and time to diagnosis for the 6-month JAQQ score. CONCLUSION Clinical measures soon after diagnosis predict short-term outcomes for patients with JIA. The JAQQ is a predictor of multiple outcomes. Time to diagnosis affects quality of life in the short term.


Pediatrics International | 2012

Value of amino-terminal pro B-natriuretic peptide in diagnosing Kawasaki disease

Ariane McNeal-Davidson; Anne Fournier; Linda Spigelblatt; Claire Saint-Cyr; Thomas S Mir; Amiram Nir; Frédéric Dallaire; Jocelyne Cousineau; Edgard Delvin; Nagib Dahdah

Background:  The aim of the present study was to investigate the diagnostic value of the N‐terminal B‐type natriuretic peptide (NT‐proBNP) in acute Kawasaki disease (KD) given that the clinical criteria and the current basic laboratory tests lack the necessary specificity for accurate diagnosis.


European Journal of Pediatrics | 2011

Fatal group A Streptococcus purpura fulminans in a child receiving TNF-α blocker

Christian Renaud; Philippe Ovetchkine; Patricia Bortolozzi; Claire Saint-Cyr; Bruce Tapiero

Inhibition of tumor necrosis factor alpha (TNF-α) is effective in the treatment of many pediatric autoimmune diseases and inflammatory conditions. Commonly available biologic agents blocking TNF-α are infliximab, etanercept, and adalimumab. These agents have changed the management of rheumatic diseases in the adult population and are being used more and more in pediatric patients as safety and efficacy have been demonstrated. Infections have been the most commonly reported adverse effects of TNF-α inhibition. Granulomatous infections such as tuberculosis are well-known complications, but serious bacterial infections are also reported. We describe a fatal case of purpura fulminans caused by group A Streptococcus in an 8-year-old child with systemic juvenile idiopathic arthritis treated with etanercept. This case highlights the clinical association of severe bacterial infection and TNF-α inhibition in children. Pediatricians should educate their patients who are treated with TNF-α blockers regarding early warning symptoms and should also have a lower threshold for initiating antibiotic therapy in case of fever.


Arthritis Care and Research | 2013

Glucocorticoid-Related Changes in Body Mass Index Among Children and Adolescents With Rheumatic Diseases

Natalie J. Shiff; Rollin Brant; Jaime Guzman; David A. Cabral; Adam M. Huber; Paivi Miettunen; J. Roth; Rosie Scuccimarri; Nathalie Alos; Stephanie A. Atkinson; Jean Paul Collet; Robert Couch; Elizabeth A. Cummings; Peter B. Dent; Janet Ellsworth; John Hay; Kristin Houghton; Roman Jurencak; Bianca Lang; Maggie Larché; Claire LeBlanc; Celia Rodd; Claire Saint-Cyr; Robert Stein; David Stephure; Shayne Taback; Frank Rauch; Leanne M. Ward

To examine the temporal and dose‐related effects of glucocorticoids (GCs) on body mass index (BMI) in children with rheumatic diseases.


Pediatric Nephrology | 2009

Renal granuloma and immunoglobulin M-complex glomerulonephritis: a case of common variable immunodeficiency?

Geneviève Benoit; Anne-Laure Lapeyraque; Hervé Sartelet; Claire Saint-Cyr; Françoise Le Deist; Elie Haddad

Common variable immunodeficiency (CVID) is characterized by reduced serum immunoglobulin levels and recurrent bacterial infections. Granulomatous infiltrations are occasionally found in the lymphoid or solid organs of affected patients, but renal involvement is rare. We present a case of possible CVID with interstitial noncaseating granuloma and immunoglobulin (IgM)-complex glomerulonephritis with a membranoproliferative pattern and with a favorable response to corticosteroids, intravenously administered immunoglobulins (IVIGs) and rituximab. CVID must be included in the differential diagnosis of renal granuloma and should be differentiated from sarcoidosis to ensure appropriate therapy.


Case Reports | 2014

Rapidly progressive aortic aneurysmal dilation in a child with systemic lupus erythematosus: too early too severe.

Soha Rached-d'Astous; Nagib Dahdah; Pierre Brochu; Claire Saint-Cyr

About 10–20% of systemic lupus erythematosus cases occur in children, often with more severe features at onset and more active disease over time compared with adults. Cardiovascular complications are common in this population but thoracic aortic aneurysms rarely occur. Although the pathophysiology of this complication remains unclear, vasculitis seems to play an important role, leading to degeneration and fibrosis of the media and formation of the aneurysm. We report the case of a 9-year-old systemic lupus erythematosus patient with important renal involvement, who underwent aortic replacement surgery for the treatment of an aortic aneurysm. This case highlights the importance of monitoring the thoracic aorta in children with systemic lupus erythematosus and the need for the development of appropriate early management strategies for this serious complication.


Pediatrics International | 2017

N-terminal pro-B-type natriuretic peptide diagnostic algorithm versus American Heart Association algorithm for Kawasaki disease

Audrey Dionne; Léamarie Meloche-Dumas; Laurent Desjardins; Jean Turgeon; Claire Saint-Cyr; Julie Autmizguine; Linda Spigelblatt; Anne Fournier; Nagib Dahdah

Diagnosis of Kawasaki disease (KD) can be challenging in the absence of a confirmatory test or pathognomonic finding, especially when clinical criteria are incomplete. We recently proposed serum N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) as an adjunctive diagnostic test.

Collaboration


Dive into the Claire Saint-Cyr's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David A. Cabral

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kiem Oen

University of Manitoba

View shared research outputs
Top Co-Authors

Avatar

Kristin Houghton

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge